GO:0072377 blood coagulation, common pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0072377 (blood coagulation, common pathway) describes the protein activation cascade that begins with activated Factor Xa and culminates in the formation of cross-linked fibrin.
• The common pathway is the convergence point of the intrinsic and extrinsic coagulation pathways, making it central to thrombin generation and clot formation.
• Key genes include F10, F5, F2, FGA, FGB, FGG, and F13A1, which encode the proteases and substrates that execute the cascade.
• Dysregulation of the common pathway contributes to venous thromboembolism, sepsis-induced coagulopathy, and bleeding disorders.
• CRISPR-based knockout, point-mutation, and knock-in models enable causal interrogation of common-pathway genes in human cells and animal models.
• Assessing common-pathway function relies on coagulation assays such as PT, aPTT, thrombin generation, and fibrinogen measurement.
Description
The blood coagulation common pathway (GO:0072377) is the final proteolytic cascade shared by the intrinsic and extrinsic arms of coagulation, beginning with the formation of activated Factor Xa and ending with the generation of a stable, cross-linked fibrin clot. This pathway is a paradigm of a protein activation cascade, in which sequential zymogen-to-protease conversions amplify an initial trigger into a robust hemostatic response. Because it integrates both initiation routes, the common pathway is a focal point for understanding how blood clots form under physiological and pathological conditions. For researchers, GO:0072377 provides a precise ontological framework to annotate genes and proteins whose functions converge on thrombin generation and fibrin formation. The pathway is not merely a linear sequence; it is embedded in feedback regulation, cofactor assembly, and crosstalk with inflammation and vascular biology. Consequently, experimental dissection of the common pathway requires tools that can perturb individual nodes and measure the resulting changes in coagulation kinetics. This article synthesizes the authoritative QuickGO definition and verified PubMed literature to describe the mechanism, key genes, disease relevance, and research methods for GO:0072377. It is intended for scientists who need a rigorous, citable overview of the common pathway and for those designing CRISPR-based experiments to test gene function within this cascade.
blood coagulation, common pathway At A Glance
| GO ID | GO:0072377 |
|---|---|
| GO term | blood coagulation, common pathway |
| Ontology | biological_process |
| Synonym | None |
| Major function | Protein activation cascade leading from Factor Xa to cross-linked fibrin |
| Key proteases | Factor Xa, thrombin (Factor IIa), Factor XIIIa |
| Key cofactors | Factor Va, calcium ions, phospholipid membranes |
| Key substrates | Prothrombin (F2), fibrinogen (FGA, FGB, FGG) |
| End product | Stable multimeric cross-linked fibrin clot |
| Upstream inputs | Intrinsic and extrinsic coagulation pathways |
What Is GO:0072377?
GO:0072377 (blood coagulation, common pathway) is defined as a protein activation cascade that contributes to blood coagulation and consists of events leading from the formation of activated Factor Xa by either the intrinsic or extrinsic pathway, to the formation of active thrombin, the cleavage of fibrinogen by thrombin, and the formation of cleaved fibrin into a stable multimeric, cross-linked complex. In simpler terms, it is the shared final stretch of the coagulation system where Factor Xa, with its cofactor Factor Va, converts prothrombin to thrombin, and thrombin then converts fibrinogen into fibrin, which is subsequently cross-linked by Factor XIIIa.
Why Is blood coagulation, common pathway Important in Cell Biology?
The common pathway is the terminal effector arm of blood coagulation, and its activity determines whether a clot forms, how large it becomes, and how quickly it is remodeled. Because both the intrinsic and extrinsic pathways converge on Factor Xa, the common pathway is a critical integration hub for hemostatic signals and a major target for anticoagulant therapy. Genetic or acquired defects in common-pathway components can cause bleeding or thrombosis, and the pathway is frequently dysregulated in sepsis, trauma, and cancer-associated coagulopathy. Thus, understanding GO:0072377 is essential for interpreting coagulation tests, developing therapeutics, and designing mechanistic studies of hemostasis.
• Provides the final common route for thrombin generation and fibrin formation.
• Integrates intrinsic and extrinsic coagulation inputs at Factor Xa.
• Mutations in common-pathway genes are associated with venous thromboembolism.
• Dysregulation contributes to sepsis-induced coagulopathy and disseminated intravascular coagulation.
• Isolated prolongation of aPTT can reflect common-pathway abnormalities and is not always a bleeding risk.
• Serves as a target for anticoagulants such as direct Factor Xa and thrombin inhibitors.
• Provides biomarkers (e.g., thrombin-antithrombin complexes) for hypercoagulable states.
• Is essential for interpreting routine coagulation tests (PT, aPTT, fibrinogen).
• Crosstalk with inflammation links coagulation to innate immune responses.
• CRISPR models enable causal testing of common-pathway gene variants.
What Happens During blood coagulation, common pathway?
Initiation at Factor Xa
In simple terms: The common pathway starts when Factor X is activated to Factor Xa by either the intrinsic or extrinsic route.
The common pathway begins with the formation of activated Factor Xa, which can be generated by the intrinsic pathway (via Factor IXa and its cofactor Factor VIIIa) or the extrinsic pathway (via tissue factor and Factor VIIa). Factor Xa is a serine protease that, once formed, assembles with its cofactor Factor Va on phospholipid membranes in the presence of calcium ions to form the prothrombinase complex. This assembly step is essential for efficient catalysis and is a key point of regulation.
Prothrombin activation to thrombin
In simple terms: Factor Xa cuts prothrombin to make thrombin, the central enzyme of clotting.
Within the prothrombinase complex, Factor Xa cleaves prothrombin (Factor II) at specific sites to release active thrombin (Factor IIa). Thrombin is a multifunctional serine protease that not only converts fibrinogen to fibrin but also activates platelets, Factors V, VIII, XI, and XIII, and protein C. The generation of thrombin is amplified by feedback activation of cofactors, ensuring a burst of thrombin sufficient for clot formation.
Fibrinogen cleavage and fibrin polymerization
In simple terms: Thrombin snips fibrinogen into fibrin, which then self-assembles into a mesh.
Thrombin cleaves fibrinopeptides A and B from the central region of fibrinogen (encoded by FGA, FGB, and FGG), exposing polymerization sites. The resulting fibrin monomers spontaneously assemble into protofibrils and then into thicker fibers, forming the structural scaffold of the clot. This step is critical for the mechanical stability of the hemostatic plug.
Factor XIIIa-mediated cross-linking
In simple terms: Factor XIIIa glues the fibrin mesh together to make it strong and stable.
Thrombin also activates Factor XIII to Factor XIIIa, a transglutaminase that introduces covalent cross-links between fibrin molecules. These cross-links stabilize the fibrin polymer into a multimeric, cross-linked complex that is resistant to mechanical stress and fibrinolysis. The formation of this stable complex is the endpoint of the common pathway as defined by GO:0072377.
Regulation and feedback
In simple terms: The common pathway is kept in check by inhibitors and feedback loops.
The common pathway is regulated by stoichiometric and dynamic inhibitors, including antithrombin, tissue factor pathway inhibitor (TFPI), and the protein C system. Thrombin generation is also modulated by positive feedback on Factors V, VIII, and XI, which amplifies the cascade. Imbalance between procoagulant and anticoagulant forces can shift the pathway toward bleeding or thrombosis.
Key Genes Involved in GO:0072377 blood coagulation, common pathway
The following genes encode the core proteases, cofactors, and substrates that execute and regulate the common pathway of blood coagulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| F10 | Encodes Factor X, the zymogen activated to Factor Xa that initiates the common pathway | Target for anticoagulants; mutations affect thrombin generation |
| F5 | Encodes Factor V, cofactor for the prothrombinase complex | Factor V Leiden is a common thrombophilia variant |
| F2 | Encodes prothrombin, the substrate for Factor Xa and precursor of thrombin | Prothrombin G20210A variant increases thrombosis risk |
| FGA | Encodes fibrinogen alpha chain, a substrate for thrombin | Mutations cause dysfibrinogenemia and bleeding |
| FGB | Encodes fibrinogen beta chain, a substrate for thrombin | Variants linked to fibrinogen levels and thrombosis |
| FGG | Encodes fibrinogen gamma chain, a substrate for thrombin | Mutations affect fibrin polymerization |
| F13A1 | Encodes Factor XIII A subunit, which cross-links fibrin | Deficiency causes delayed bleeding; variants affect clot stability |
| F13B | Encodes Factor XIII B subunit, carrier for the A subunit | Rare variants associated with bleeding |
| SERPINC1 | Encodes antithrombin, a major inhibitor of thrombin and Factor Xa | Deficiency causes severe thrombophilia |
| PROC | Encodes protein C, which inactivates Factors Va and VIIIa | Deficiency predisposes to venous thrombosis |
| PROS1 | Encodes protein S, cofactor for protein C | Deficiency increases thrombosis risk |
| TFPI | Encodes tissue factor pathway inhibitor, which regulates the extrinsic pathway and common pathway | Genetic variation associated with venous thromboembolism |
| F11 | Encodes Factor XI, which amplifies thrombin generation | Deficiency causes mild bleeding; target for antithrombotic therapy |
| F8 | Encodes Factor VIII, cofactor for Factor IXa in the intrinsic pathway | Deficiency causes hemophilia A; affects common pathway input |
| F9 | Encodes Factor IX, protease that activates Factor X | Deficiency causes hemophilia B |
| VWF | Encodes von Willebrand factor, which stabilizes Factor VIII | Deficiency causes von Willebrand disease |
| PLG | Encodes plasminogen, the precursor of plasmin that degrades fibrin | Regulates clot lysis and fibrinolysis |
How Is blood coagulation, common pathway Regulated?
The common pathway is regulated at multiple levels. Antithrombin (SERPINC1) directly inhibits thrombin and Factor Xa, and its activity is enhanced by heparin. The protein C pathway, comprising protein C (PROC), protein S (PROS1), and thrombomodulin, inactivates Factors Va and VIIIa, thereby dampening thrombin generation. Tissue factor pathway inhibitor (TFPI) limits the extrinsic pathway and indirectly the common pathway. Positive feedback loops involving thrombin-mediated activation of Factors V, VIII, and XI amplify the cascade, while fibrinolysis mediated by plasminogen activators removes fibrin. Inflammatory mediators can also modulate common-pathway activity, contributing to sepsis-induced coagulopathy.
blood coagulation, common pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| F5 | Factor V Leiden thrombophilia | Knock-in of Factor V Leiden in HAP1 or iPSC-derived hepatocytes |
| F2 | Prothrombin G20210A-associated thrombosis | Point-mutation knock-in in HepG2 cells |
| FGA | Dysfibrinogenemia and bleeding | Knockout of FGA in HepG2 followed by fibrinogen assays |
| F13A1 | Factor XIII deficiency with delayed bleeding | Knockout in HEK293T and cross-linking assays |
| TFPI | Venous thromboembolism risk | Overexpression or knockout in endothelial cells |
Venous Thromboembolism and Thrombophilia
Genetic variants in common-pathway genes, including F5 (Factor V Leiden) and F2 (prothrombin G20210A), are established risk factors for venous thromboembolism. Population-based studies have also linked genetic variation in TFPI to venous thromboembolism among middle-aged and older adults. Hypercoagulable states can arise from acquired conditions such as cancer, pregnancy, and immobility, leading to excessive thrombin generation through the common pathway.
Sepsis-Induced Coagulopathy
Sepsis-induced coagulopathy is characterized by dysregulated coagulation, including activation of the common pathway, consumption of coagulation factors, and impaired fibrinolysis. Inflammatory cytokines induce tissue factor expression and downregulate anticoagulant pathways, tipping the balance toward thrombosis and disseminated intravascular coagulation. Monitoring common-pathway markers such as thrombin-antithrombin complexes can aid diagnosis and management.
Bleeding Disorders
Deficiencies or mutations in common-pathway components, such as fibrinogen (FGA, FGB, FGG) or Factor XIII (F13A1), can cause bleeding diatheses. Isolated prolongation of activated partial thromboplastin time (aPTT) may indicate defects in the intrinsic or common pathway and requires careful evaluation to distinguish bleeding risk from incidental findings. Acquired bleeding can also result from liver disease, vitamin K deficiency, or disseminated intravascular coagulation.
From blood coagulation, common pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of F10 reduce thrombin generation? | CRISPR knockout of F10 in HepG2 cells |
| Does the Factor V Leiden mutation alter clot stability? | Point-mutation knock-in of F5 in iPSC-derived hepatocytes |
| Can a tagged Factor XIII be used to track cross-linking? | Knock-in of a fluorescent tag at the F13A1 locus |
| Does overexpression of TFPI inhibit common-pathway activity? | Overexpression of TFPI in endothelial cells |
| Which genes are essential for fibrin formation? | Genome-wide CRISPR library screening in a fibrinogen reporter line |
| Does a patient variant in FGB affect fibrin polymerization? | Knock-in of the variant in HepG2 cells followed by turbidity assays |
How to Study the blood coagulation, common pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| PT/aPTT | Clotting time via extrinsic/intrinsic pathways | Diagnosis of coagulation disorders |
| Thrombin generation assay | Kinetics of thrombin production | Assessment of hypercoagulability |
| Fibrinogen assay | Fibrinogen concentration and function | Dysfibrinogenemia screening |
| Mass spectrometry | Proteolytic cleavage products | Mapping coagulation protease substrates |
| CRISPR knockout | Gene function loss | Testing essentiality of common-pathway genes |
| CRISPR knock-in | Specific variant effects | Modeling patient mutations |
| Fluorescence imaging | Fibrin network structure | Visualizing clot formation |
| Genotyping | Genetic variants | Thrombophilia risk assessment |
Coagulation Assays
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) are standard tests that assess the extrinsic and intrinsic pathways, respectively, and both reflect common-pathway function. Thrombin generation assays measure the kinetics of thrombin production and can detect hyper- or hypocoagulable states. Fibrinogen concentration and fibrin polymerization assays evaluate the substrate and end product of the common pathway.
Genetic and Genomic Approaches
Targeted genotyping and next-generation sequencing can identify variants in common-pathway genes associated with thrombosis or bleeding. Genome-wide association studies have linked common variants to venous thromboembolism risk. CRISPR-based screens can systematically test the contribution of each gene to common-pathway activity.
Proteomic and Mass Spectrometry Methods
Plasma proteolysis pathways comprising blood coagulation proteases can be mapped by mass spectrometry to identify cleavage events and substrates. Targeted proteomics can quantify thrombin-antithrombin complexes and other activation markers. These methods provide a systems-level view of common-pathway activity in health and disease.
Cell-Based and Imaging Methods
Fluorescence microscopy can visualize fibrin network formation and platelet aggregation in vitro. Live-cell imaging of tagged coagulation factors in CRISPR knock-in cell lines allows real-time tracking of protein localization and activation. These approaches complement biochemical assays and provide spatial information.
How CRISPR Can Be Used to Study GO:0072377 blood coagulation, common pathway
Knockout
CRISPR knockout of common-pathway genes such as F10, F2, or FGA in hepatic cell lines can abolish thrombin generation and fibrin formation, providing causal evidence for their essential roles. Knockout models are also useful for validating drug targets and for studying compensatory mechanisms.
Point Mutation
Point mutations that mimic human variants, such as Factor V Leiden (F5) or prothrombin G20210A (F2), can be introduced by CRISPR base editing or homology-directed repair to study their effects on common-pathway activity. These models help distinguish pathogenic from benign polymorphisms.
Knock-in
Knock-in of reporter tags or patient-specific mutations allows tracking of protein expression, localization, and function in live cells. For example, tagging endogenous Factor XIII with a fluorescent protein enables real-time visualization of fibrin cross-linking.
Overexpression
Overexpression of common-pathway inhibitors such as TFPI or SERPINC1 can be achieved by CRISPR activation or lentiviral delivery to study their impact on thrombin generation. Overexpression models are valuable for testing gain-of-function mechanisms and therapeutic candidates.
How EDITGENE Supports blood coagulation, common pathway Research
Researchers studying blood coagulation, common pathway-related genes often need to determine whether a candidate gene is causally involved in thrombin generation, fibrin formation, or clot stability. EDITGENE provides a comprehensive suite of CRISPR services to create precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for blood coagulation, common pathway research.
Frequently Asked Questions About blood coagulation, common pathway
What is GO:0072377 blood coagulation, common pathway?
GO:0072377 is a Gene Ontology biological process term describing the protein activation cascade that starts with Factor Xa and leads to thrombin generation, fibrinogen cleavage, and cross-linked fibrin formation.
What genes are involved in the blood coagulation common pathway?
Key genes include F10, F5, F2, FGA, FGB, FGG, F13A1, and F13B, which encode the proteases, cofactors, and substrates of the cascade.
How is the common pathway different from the intrinsic and extrinsic pathways?
The common pathway is the shared final segment where both intrinsic and extrinsic pathways converge at Factor Xa activation.
What diseases are associated with common pathway defects?
Venous thromboembolism, sepsis-induced coagulopathy, and bleeding disorders such as dysfibrinogenemia and Factor XIII deficiency.
What laboratory tests measure common pathway function?
Prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin generation assays, and fibrinogen assays.
Can CRISPR be used to study common pathway genes?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of gene function in the common pathway.
What is the role of thrombin in the common pathway?
Thrombin cleaves fibrinogen to fibrin and activates Factor XIII, which cross-links fibrin to form a stable clot.
How is the common pathway regulated?
It is regulated by antithrombin, the protein C system, tissue factor pathway inhibitor, and feedback activation of cofactors.
What is the end product of the common pathway?
The end product is a stable multimeric, cross-linked fibrin complex.
Why is the common pathway important for drug development?
It is the target of anticoagulants such as direct Factor Xa and thrombin inhibitors, and its components are biomarkers for thrombosis.
Conclusion
GO:0072377 (blood coagulation, common pathway) is the terminal, convergent cascade of hemostasis, responsible for thrombin generation and the formation of a stable fibrin clot. Its components are genetically and clinically important, with variants linked to thrombosis and bleeding disorders. Understanding its mechanism, regulation, and disease associations is essential for basic and translational research. CRISPR-based models offer powerful tools to dissect the causal roles of common-pathway genes and to test therapeutic hypotheses. EDITGENE provides end-to-end services to generate such models, enabling researchers to move from candidate gene to functional insight efficiently.
References
- 1. Winter WE et al.. 2017. Coagulation Testing in the Core Laboratory.. Lab Med 48(4):295-313 PMID: 29126301
- 2. Williams B et al.. 2024. Sepsis-Induced Coagulopathy: A Comprehensive Narrative Review of Pathophysiology, Clinical Presentation, Diagnosis, and Management Strategies.. Anesth Analg 138(4):696-711 PMID: 38324297
- 3. Santoro RC et al.. 2023. Isolated Prolongation of Activated Partial Thromboplastin Time: Not Just Bleeding Risk!. Medicina (Kaunas) 59(6) PMID: 37374373
- 4. Petros S. 2021. [Pathophysiology of bleeding].. Med Klin Intensivmed Notfmed 116(6):475-481 PMID: 34402917
- 5. Yang L et al.. 2016. A plasma proteolysis pathway comprising blood coagulation proteases.. Oncotarget 7(27):40919-40938 PMID: 27248165
- 6. He XY et al.. 2024. Genetic associations of protein-coding variants in venous thromboembolism.. Nat Commun 15(1):2819 PMID: 38561338
- 7. Manderstedt E et al.. 2022. Genetic variation of the blood coagulation regulator tissue factor pathway inhibitor and venous thromboembolism among middle-aged and older adults: A population-based cohort study.. Res Pract Thromb Haemost 6(7):e12842 PMID: 36381289
- 8. Bick RL. 1994. Hypercoagulability and thrombosis.. Med Clin North Am 78(3):635-65 PMID: 8170263
